Clinical Trial Update: A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib [Phase 3]

View source ↗

Summary

Clinical trial update for a Phase 3 study companion protocol exploring breast cancer aberrations with CDK4/6 inhibition (ribociclib) that has been terminated wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Ribociclib (ribociclib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Breast Cancer | Phase 3 | Status: TERMINATED | Results posted: 2020-05-15